Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Rating of “Moderate Buy” by Analysts

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have received a consensus recommendation of “Moderate Buy” from the ten analysts that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $11.44.

A number of analysts have recently issued reports on MRVI shares. Robert W. Baird lifted their price objective on shares of Maravai LifeSciences from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Thursday, May 9th. Craig Hallum assumed coverage on Maravai LifeSciences in a research note on Wednesday, April 10th. They set a “buy” rating and a $15.00 target price for the company.

Maravai LifeSciences Trading Down 2.3 %

Shares of NASDAQ MRVI opened at $7.07 on Tuesday. Maravai LifeSciences has a twelve month low of $4.52 and a twelve month high of $13.31. The company has a quick ratio of 10.47, a current ratio of 11.32 and a debt-to-equity ratio of 0.71. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -7.14 and a beta of 0.06. The company’s fifty day moving average is $8.85 and its 200-day moving average is $7.54.

Maravai LifeSciences (NASDAQ:MRVI) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.05). Maravai LifeSciences had a negative net margin of 47.81% and a negative return on equity of 4.28%. The company had revenue of $64.18 million during the quarter, compared to analyst estimates of $60.84 million. Equities research analysts predict that Maravai LifeSciences will post -0.15 EPS for the current year.

Insider Activity

In other Maravai LifeSciences news, Director Gtcr Investment Xi Llc sold 9,940,974 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $9.81, for a total value of $97,520,954.94. Following the transaction, the director now directly owns 20,150,005 shares of the company’s stock, valued at approximately $197,671,549.05. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.63% of the company’s stock.

Institutional Investors Weigh In On Maravai LifeSciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP lifted its position in shares of Maravai LifeSciences by 2.6% during the 3rd quarter. Wellington Management Group LLP now owns 70,658 shares of the company’s stock worth $707,000 after buying an additional 1,779 shares during the last quarter. QRG Capital Management Inc. lifted its holdings in shares of Maravai LifeSciences by 11.7% in the first quarter. QRG Capital Management Inc. now owns 17,143 shares of the company’s stock worth $149,000 after acquiring an additional 1,796 shares during the last quarter. M&T Bank Corp boosted its stake in shares of Maravai LifeSciences by 17.3% in the 4th quarter. M&T Bank Corp now owns 20,107 shares of the company’s stock valued at $131,000 after purchasing an additional 2,972 shares in the last quarter. Performa Ltd US LLC grew its holdings in shares of Maravai LifeSciences by 112.4% during the 4th quarter. Performa Ltd US LLC now owns 6,000 shares of the company’s stock valued at $39,000 after purchasing an additional 3,175 shares during the last quarter. Finally, Handelsbanken Fonder AB increased its position in Maravai LifeSciences by 15.4% during the 4th quarter. Handelsbanken Fonder AB now owns 25,500 shares of the company’s stock worth $167,000 after purchasing an additional 3,400 shares in the last quarter. 50.25% of the stock is currently owned by institutional investors.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.